Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.65 |
| ▸ | SELP | P16109 | 2/20 | 0.65 |
| ▸ | SELL | P14151 | 2/20 | 0.65 |
| ▸ | SELE | P16581 | 5/20 | 0.65 |
| ▸ | MAG | P20916 | 5/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17563502 | 0.96 | SIGLEC7 (0.60) | SIGLEC7SELPSELLSELEMAG | |
| SCHEMBL26172909 | 0.94 | SIGLEC7 (0.66) | SIGLEC7SELPSELLSELEMAG | |
| SCHEMBL19453264 | 0.92 | SELE (0.70) | SIGLEC7SELPSELLSELEMAG | |
| SCHEMBL25068789 | 0.91 | SIGLEC7 (0.68) | SIGLEC7SELPSELLSELEMAG | |
| SCHEMBL14331141 | 0.90 | SELP (0.70) | SIGLEC7SELPSELLSELEMAG | |
| SCHEMBL14518953 | 0.90 | SELP (0.70) | SIGLEC7SELPSELLSELEMAG | |
| SCHEMBL14268468 | 0.90 | SELP (0.70) | SIGLEC7SELPSELLSELEMAG | |
| SCHEMBL22763983 | 0.90 | SELP (0.72) | SIGLEC7SELPSELLSELEMAG | |
| SCHEMBL13541587 | 0.90 | SELP (0.72) | SIGLEC7SELPSELLSELEMAG | |
| SCHEMBL31010809 | 0.90 | SELP (0.71) | SIGLEC7SELPSELLSELEMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160067357-A1 | DETECTION OF HIGH RISK DRUSEN | APELLIS PHARMACEUTICALS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20150133395-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | ROSEMOUNT INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133395-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | SIGLEC7 2457/4885SELP 3759/4885SELL 4004/4885 |
| US-20160067357-A1 | DETECTION OF HIGH RISK DRUSEN | IL17A, EXOSC4, CFB | SIGLEC7 91/4885SELP 197/4885SELL 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.